WednesdayGS
Bioassays for Bispecifics – Double the Trouble or Double the Fun?
Date
April 29, 2020
This product is not available for individual purchase, but it is available as part of the following products:
The structures and functions of modern biotherapeutics are becoming increasingly complex. A new generation of diverse multi-modal molecules has quickly emerged, where single molecules can bind multiple targets, harbor multiple activities, have combinatorial/synergistic activities, or all of the above. The complexity of multi-modal biotherapeutics brings about new challenges for bioassay development, as well as exciting opportunities for the application of novel assay formats and technologies.
Speakers
Amgen Inc.
AbbVie Inc.
Pfizer, Inc.
Pfizer, Inc.
Genentech, a Member of the Roche Group
Amgen Inc.
CDER, FDA
Health Canada
Tracks
Related Products
Bioassays for New Therapies
The number and diversity of biotherapeutic modalities continues to increase. These represent complex modalities such as peptide and peptide conjugates, antisense oligonucleotides, DNA- and RNA-based therapies, drug conjugates, as well as viral vector-based therapeutics…
Bioassays for Cell and Gene Therapy
With increasing numbers of cell and gene therapy products in development and entering commercialization, more and more sponsors are facing a unique set of challenges of developing bioassays for cell and gene therapy products…
Bioassay Development Strategy for Bispecific Antibodies: Use of SPR Technology
ELISA binding assays are often used as fit-for-purpose potency assays at early stage of product development for monoclonal antibody and bispecific antibody products…
